Int J Ayu Pharm Chem
ISSN 2350-0204
www.ijapc.com

REVIEW ARTICLE

Integrating Generative AI and Traditional Wisdom: A Computational Review of *De Novo* Drug Discovery from Ayurvedic Phytomolecules, Safety Assessment, and Validation Frameworks

Author: Yogesh Dilip Madgulwar[1]

Co Authors: Ankeeta Sudhakar Pawar[2]

[1]Dept.of Rasashastra Bhaishajyakalpana, Seth Chandanmal Mutha Aryangla Vaidyak Mahavidyalaya, Satara, MP, India
[2]Dept.of Rasashastra Bhaishajyakalpana, Rajashri Ayurved Medical College, Mehkar Buldhana, MS, India

ABSTRACT

Introduction- Ayurveda offers a rich repository of therapeutically active phytomolecules, yet traditional drug discovery from these sources is limited by empirical approaches and slow validation. Advances in Generative Artificial Intelligence (GAI) enable systematic exploration, optimization, and validation of Ayurvedic phytomolecules through modern computational methods. Objective-To review the integration of Generative AI with Ayurvedic knowledge for de novo drug discovery, emphasizing computational lead generation, safety assessment, and validation frameworks based on reverse pharmacology and systems biology. Methods-A computational review of literature on GAI-driven drug discovery and Ayurvedic phytochemistry was conducted, evaluating generative models, QSAR/QSPR, molecular docking, network pharmacology, and predictive toxicology within translational validation frameworks. Results- GAI effectively generates drug-like analogues derived from Ayurvedic phytomolecules while retaining polypharmacological properties. In silico safety models enable early prediction of toxicity, pharmacokinetics, and herb–drug interactions, improving validation efficiency and reducing development attrition. Conclusion-The convergence of Generative AI and Ayurvedic wisdom provides a scalable, evidence-based framework for de novo drug discovery, advancing integrative medicine and supporting safer, multi-target therapeutic development with regulatory and global health relevance.

Received 18th January 2026 Accepted 08th March 2026 Published 10th March 2026

INTRODUCTION

The contemporary pharmaceutical industry faces a persistent and critical challenge- the prolonged timeline, exorbitant cost, and high attrition rate, Immense Chemical Space, Data Silos and Interpretation associated with developing novel therapeutic agents[1]. The conventional drug discovery pipeline typically spans over a decade, with failure rates reaching approximately 90% for optimized candidates during clinical trials, often due to unexpected toxicity or inadequate efficacy [2]. This systemic bottleneck necessitates a fundamental

REVIEW ARTICLE

paradigm shift in how novel molecules are designed, screened, and validated.

Generative Artificial Intelligence (GAI) has emerged as the pivotal technology driving an efficiency revolution in molecular sciences[1]. By leveraging advanced statistical modeling and deep learning, GAI enables the accelerated exploration of the vast "chemical universe," which is conservatively estimated to contain up to **one nonillion** drug-like molecules[2]. In contrast to traditional rule-based molecular assembly and enumeration approaches, GAI models can generate molecules *de novo* that are predicted to possess specific desirable pharmacological properties[3]. **Digital Twins:** AI generates virtual patient models (Digital Twins) to simulate clinical trial outcomes before human testing, reducing participant requirements by up to **35%** in some studies. The strategic application of AI promises to significantly compress research and development (R&D) timelines and enhance the accuracy of compound screening, thereby optimizing the entire journey of a medicine from initial idea to patient accessibility [1] .

Natural Products, Ayurveda, and the Search for Novel Scaffolds

Natural products (NPs), including those derived from traditional medical systems such as Ayurveda, represent an invaluable reservoir of chemical diversity and biologically validated therapeutic potential [5]. Ayurvedic wisdom, accumulated over millennia, offers an underutilized yet highly promising avenue for developing safe and effective drugs to address global health challenges. Historically, bioactive NP scaffolds have served as the molecular inspiration for synthetic chemistry efforts, leading to diversity-oriented synthesis (DOS) and function-oriented synthesis (FOS) of NP-like libraries[6].

Ethnopharmacology- Thousands of years of use in traditional practices provide a historical guide to potential efficacy and safety, which can significantly de-risk early-stage drug discovery and suggest specific targets.

The integration of GAI into this domain aims not merely to replicate existing chemical space but to accelerate the discovery of truly novel chemical scaffolds. Current computational approaches are now focused on refining NP leads, synthesizing Pseudo-Natural Products" (pseudo-NPs) developing optimization frameworks that balance novelty, activity, and synthetic feasibility [8] . By using AI-driven technologies for phytochemical analysis and quality control, the authenticity and efficacy of raw materials used in Ayurvedic preparation can be assured, thereby fostering consumer trust in these pharmaceutical preparations [7] .

The Reverse Pharmacology (RP) Paradigm and AI Synergy

Traditional drug discovery typically follows a "forward" path, starting with a target and progressing to a clinical observation. Conversely, Reverse Pharmacology (RP) offers a major paradigm shift, initiating the process with known or serendipitous clinical phenomena resulting from traditional interventions and then working backward to establish the specific molecular mechanisms and active compounds[8]. RP is defined as an organized path

REVIEW ARTICLE

rooted in clinical experiences, experimental observations, and structured data.

The synergy between RP and GAI is strategically important for mitigating R&D risk. The primary expenditure and delay in traditional R&D stem from failures in the later clinical phases. By commencing lead generation and validation using molecules derived from Ayurvedic interventions that already possess documented clinical efficacy, the RP-AI approach inherently reduces the early-stage clinical uncertainty associated with *de novo* discovery from synthetic libraries. This integrated approach leverages GAI to generate optimized, potentially patentable analogs of the clinically effective molecule, allowing the development process to rapidly move toward modern validation protocols. This structure facilitates a faster and more cost-effective development model for standardized phytomedicines.

SCOPE AND OBJECTIVES

This paper provides a detailed, technical review of the role of Generative AI in the *de novo* design of drug molecules derived from Ayurvedic herbs. It critically examines the established computational methodologies, including the architectures for molecular generation and the advanced *in silico* techniques necessary for safety and efficacy assessment [9]. A particular focus is placed on assessing the unique challenges and proposed solutions for ensuring the safety and efficacy of complex herbal and herbomineral formulations against modern regulatory criteria, specifically utilizing the framework of the Introduction, Methods, Results, and Discussion (IMRAD) structure.

MATERIALS AND METHODS

Data Infrastructure for Ayurvedic Phytochemicals and Preprocessing

Structured Chemical Databases

Effective GAI training and computational screening are predicated on access to high-quality, structured data. Digital repositories that catalog the chemical constituents of medicinal plants, such as the Indian Medicinal Plants, Phytochemistry and Therapeutics (IMPPAT) database, serve as crucial starting points[10] IMPPAT, for instance, provides a culmination of efforts to digitize traditional Indian medicine, offering an integrated platform where cheminformatics principles can be applied to accelerate natural product-based drug discovery. Cheminformatic analysis of such databases has yielded filtered subsets of potentially druggable phytochemicals- or example, 960 constituents identified in IMPPAT were deemed suitable candidates for novel prospective drugs based on drug-likeliness and physicochemical scoring schemes.

Molecular Representations and Data Enhancement

For generative models to function, chemical entities must be converted into standardized, machine-readable representations. The Simplified Molecular-Input Line-Entry System (SMILES) is critical, encoding both the structural and chemical properties of molecules, and forming the basis for many machine learning algorithms in drug research[11]. For advanced 3D molecular generation tasks, data must be processed into graph representations and 3D conformations.

However, the efficacy of AI integration is fundamentally challenged by the inherent characteristics of Ayurvedic data. Clinical and

REVIEW ARTICLE

biomedical data from traditional medicine are often complex, heterogeneous, poorly annotated, and lacking structure. This lack of standardization in Ayurvedic practices and the poor quality of available data make it difficult to train robust AI algorithms. To compensate for small or sparse datasets, data augmentation techniques are necessary. For instance, the Synthetic Minority Over-sampling Technique (SMOTE) has been successfully employed to generate new instances of Ayurvedic formulas to balance datasets used in supervised machine learning protocols.

Generative AI Architectures for *De Novo* Molecular Design

The goal of GAI in this context is the high-throughput generation of novel molecules optimized for target activity, ADMET properties, and synthetic feasibility, often utilizing traditional phytomolecules as starting scaffolds or training anchors. Key deep learning architectures are leveraged to achieve this goal[12].

Variational Autoencoders and Generative Adversarial Networks

Variational Autoencoders (VAEs) use an encoder-decoder structure to map molecular structures into a smooth, continuous latent space, which facilitates the targeted navigation and optimization of chemical properties [13]. By manipulating vectors in this latent space, researchers can efficiently generate structural analogs of Ayurvedic leads with modified properties. **Generative Adversarial Networks (GANs)**, conversely, rely on the competitive interaction between a generator, which proposes new compounds, and a discriminator, which evaluates their realism against existing chemical data. This feedback loop enables GANs to generate highly realistic, novel compounds that maintain desirable property profiles [14].

Diffusion Models for 3D Molecular Generation

Recent advancements have highlighted the transformative potential of Diffusion models are powerful generative AI tools that create realistic data (like images, audio, video) by learning to reverse a noise-adding process, essentially turning random static into meaningful content through step-by-step denoising, famously powering text-to-image models like Dall-E and Stable diffusion . They work by first corrupting real data with noise (forward process) and then training a neural network to learn how to meticulously remove that noise (reverse process), allowing them to generate high-quality, novel samples from pure noise making them highly effective for *de novo* design and computational chemistry applications[15].

Reinforcement Learning Optimization

Reinforcement Learning (RL) algorithms are increasingly integrated into the generative workflow to achieve goal-directed optimization. RL refines molecular synthesis paths and compound design strategies through iterative feedback loops, ensuring that the generated molecules are optimized not just for novelty but also for specific biological criteria, such as maximizing target affinity or minimizing off-target toxicity[16].

The following table summarizes the comparative strengths and limitations of these dominant GAI architectures.

Table 1 Comparative Analysis of Generative AI Architectures for Molecular Discovery

Model Type	Mechanism	Application in Natural Products	Key Limitation
Variational Autoencoders (VAEs)	Encoder/Decoder mapping data to a latent space	Smooth navigation and optimization in chemical space	Generated structures may lack

			validity or chemical correctness
Generative Adversarial Networks (GANs)	Generator (creating data) vs. Discriminator (validating data) competition	Realistic molecular generation from existing chemical data	Susceptible to mode collapse (limited diversity)
Diffusion Models (e.g., EDM)	Stepwise denoising process based on E(n) equivariant principles	High fidelity 3D molecular generation and conformation sampling	High computational overhead and reliance on precise 3D data

AI-Driven Assessment Methodologies (Safety and Efficacy)

***In Silico* ADMET and Druglikeness Screening**

Filtering GAI-generated compounds based on favorable drug like properties is mandatory before experimental validation. This initial screening assesses Absorption , Distribution, Metabolism, Excretion, and Toxicity (ADMET) using machine learning platforms like ADMET-AI, which provides fast and accurate predictions [17]. This step ensures compliance with basic pharmacokinetic viability, including criteria such as Lipinski's Rule of Five (Ro5), which assesses key physicochemical properties like molecular weight and hydrogen bond counts.

Detailed *In Silico* Validation Protocol

Promising leads identified through GAI and ADMET filtering require rigorous biophysical validation:

Molecular Docking: Tools such as Auto Dock Vina are used to predict the binding pose and affinity of lead compounds against specific therapeutic targets (e.g., enzymes, receptors, or viral proteins such as M^{pro} or RNA-dependent RNA polymerase (RdRp). Receptor grid boxes are carefully defined around co-crystallized ligands to focus the prediction on the active site.Binding energies are compared against known inhibitors to quantify efficacy potential [18] .

Molecular Dynamics (MD) Simulation: MD simulations are essential to move beyond static docking predictions and assess the stability and dynamic behavior of the protein-ligand complex over time (e.g., 20 ns runs). Software packages like GROMACS, utilized with appropriate force fields (e.g., CHARMM36), enable the calculation of dynamic metrics. These include Root Mean Square Deviation (RMSD) for structural stability, Radius of Gyration (RoG) for ligand compactness, and the analysis of hydrogen bond occupancy and interaction energies **LJ-SR (Lennard-Jones short-range)** to understand the molecular mechanism of binding [19] .

Predictive Toxicology: QSAR vs. QKAR

Computational toxicology has traditionally relied on Quantitative Structure–Activity Relationships (QSARs), which predict toxicological effects based solely on chemical structure. However, QSAR's reliance on structure limits its utility, particularly for complex natural product derivatives where small structural modifications can lead to significant biological activity changes [20] .

A more robust framework is offered by Quantitative Knowledge–Activity Relationships (QKARs), which leverages domain-specific knowledge and text embeddings alongside structural data. QKAR models, developed for critical endpoints like Drug-Induced Liver Injury (DILI) and Drug-Induced Cardiotoxicity

REVIEW ARTICLE

(DICT), analyze large datasets integrating chemical structure, pharmacological pathways, molecular pathways, and known interaction patterns. This integration provides enhanced prediction accuracy by offering valuable mechanistic insights regarding potential Drug-Herb Interactions (DHIs), which is crucial for complex mixtures where limited pharmacokinetic data is available for individual constituents.

RESULTS

GAI Performance Metrics and Novelty Generation

Novelty and Scaffold Diversity

One of the primary goals of GAI is to discover novel chemical scaffolds, moving beyond the biases inherent in reproducing known structures. Evaluation metrics show that advanced generative models, particularly diffusion-based models, are highly successful in achieving this objective. Studies demonstrate that diffusion-based models consistently yield high novelty ratios, often exceeding 90%, and achieve high scaffold diversity scores (above 0.95) [21] . This high degree of distinctness from the training data confirms the utility of GAI in finding *truly novel* structural classes that have not been previously explored.

Computational Screening and Repurposing Success

AI/ML frameworks also prove highly effective in identifying off-target interactions, which is essential for drug repurposing—finding new therapeutic applications for existing compounds or novel phytomolecules. This computational repurposing methodology utilizes multiple orthogonal target prediction methods, successfully identifying tens of thousands of off-target interactions. Targets frequently predicted include G protein-coupled receptors (GPCRs), enzymes, and kinases. The confirmation of numerous predicted off-target interactions in *in vitro* studies validates the accuracy and utility of the computational screening pipeline for identifying novel therapeutic indications.

In Silico Validation of Phytochemical Leads

The application of the defined *in silico* validation protocol (ADMET, Docking, MD) has successfully identified potent lead candidates from Ayurvedic sources. For example, the computational screening of phytochemicals from *Onosma bracteata* Wall. against SARS-CoV-2 targets demonstrated that specific compounds, such as Pulmonarioside C (9), exhibited superior binding affinity against viral targets RdRp, and Spike glycoprotein) compared to established antiviral controls [24]. Subsequent MD simulations further confirmed the structural stability and favorable interactions of these complexes over a 20 ns period. This rigorous computational validation provides the foundational data necessary to establish a compound's inhibitory potential and justifies its progression to wet-lab experimentation [22].

Safety Prediction Outcomes- The QKAR Advantage

The reliability of toxicity prediction for natural product derivatives is significantly enhanced by utilizing the QKAR framework. Comparative studies rigorously demonstrate that QKAR models consistently outperform traditional QSAR models in predicting critical toxicity endpoints, notably Drug-Induced Liver Injury (DILI) and Drug-Induced Cardiotoxicity (DICT).

The improved performance of QKAR stems from its ability to integrate complex domain knowledge. This characteristic is particularly vital for natural products, where the chemical structures of active constituents

can be highly similar but their biological or toxicological profiles diverge significantly due to subtle molecular variations or contextual factors. QKAR demonstrated a superior capability in differentiating drug pairs that possessed analogous chemical structures but exhibited disparate liver toxicity profiles. This predictive granularity provides crucial risk differentiation, a necessity for advancing novel phytomolecules that often fail traditional structure-based toxicity screening due to the limitations of QSAR models.

Structural Challenges of Ayurvedic Data Integration

Despite technological progress, the integration of AI with Traditional Knowledge Systems (TKS) such as Ayurveda faces severe data-centric limitations, significantly constraining the real-world deployment of AI models.

Heterogeneity and Standardization Failure

A fundamental technical barrier is the poor quality, heterogeneity, and lack of structure in historical Ayurvedic clinical and biomedical data. These issues include inconsistent ontologies across various TM systems and evidence heterogeneity, leading to small, ill-annotated datasets. When the training data lacks fidelity or is structurally biased, AI models tend to suffer from structural homogenization, limiting their ability to generate truly novel scaffolds and instead reproducing known, or potentially biased, chemical knowledge. This deficiency in the foundational dataset compromises model robustness and restricts successful prospective external validation.

Linguistic and Contextual Barriers

Beyond chemical data, AI systems face significant difficulties in analyzing the vast volume of original Ayurveda literature written in Sanskrit. Accurate machine translation and contextual interpretation of complex Ayurvedic concepts, such as individualized constitution (*Prakriti*) and specific clinical applications, are crucial but currently challenging. While efforts like the Ayush Grid and Ayurgenomics are advancing standardization and digital infrastructure , these linguistic and contextual barriers still prevent seamless integration of holistic Ayurvedic principles into standard computational pharmacology pipelines.

ASSESSMENT AND DISCUSSION

Rigorous Safety and Efficacy Validation Frameworks

The Criticality of QKAR for Herbal Safety

The clinical use of herbal products is complicated by the fact that they are typically complex mixtures of constituents with diverse pharmacological properties and limited available pharmacokinetic data. This complexity poses a severe challenge to safety assessment, particularly in predicting adverse drug reactions and potential drug-herb interactions (DHIs)[23] .

The adoption of the QKAR framework is not merely an improvement but an absolute necessity for the safe advancement of Ayurvedic-derived drugs. By integrating domain-specific knowledge- derived from traditional texts and mechanistic pharmacological data- QKAR models provide the crucial mechanistic differentiation required to accurately assess toxicity (DILI, DICT) and predict potential interactions with conventional drugs. The analysis of large-scale chemical structure, pathway information, and known interaction patterns allows AI to return potential risks associated with complex DHIs, guiding researchers toward safer compound modifications.

Addressing Herbo mineral Complexity

REVIEW ARTICLE

The assessment of complex formulations, including poly-herbal and specialized herbomineral preparations (Rasashastra) , requires AI to operate beyond the prediction of single-molecule activity. Predictive methodologies must employ sophisticated Network Pharmacology approaches integrated with machine learning to accurately model the polypharmacological effects of multiple constituents acting synergistically. Furthermore, AI tools are required to analyze and integrate diverse 'omics' datasets (genomic, metabolomic, ethnobotanical information) to automate the identification and quantification of all phytochemicals, assess their cumulative toxicity, and predict complex interactions within the formulation. This comprehensive, systems-level approach is vital for ensuring the efficacy and mitigating the risks associated with multi-component traditional medicines.

Validating GAI Hypotheses via Reverse Pharmacology (RP)

The integration of GAI-derived leads into the Reverse Pharmacology validation paradigm offers the most structurally sound approach for drug development from traditional medicine. RP provides the critical organizational structure for subsequent clinical validation. GAI accelerates RP by quickly generating highly optimized analogs of molecules that have existing clinical efficacy. These GAI-derived compounds, filtered by rigorous QKAR and ADMET screening, are then fed into the later stages of the RP pipeline, specifically Stage 4 (isolation and testing of active compounds) and subsequent Randomized Controlled Trials (RCTs) (Stage 3) [24].

The primary consequence of this AI-RP loop is the expedited development and regulatory standardization of phytomedicines. By identifying and optimizing active compounds *in silico* early in the process for high modern metrics (target specificity, ADMET), the resulting molecule is inherently more suitable for use as a marker for standardization and quality control, thereby accelerating the transition of traditional remedies into globally recognized, evidence-based pharmaceuticals.

Ethical, Governance, and Regulatory Compliance

Ethical Imperatives and Algorithmic Bias

The rapid development of AI in drug discovery introduces significant ethical considerations. Any ethical evaluation framework must be centered on the core principles of autonomy, justice, non-maleficence and beneficence. Key ethical concerns specific to the integration of AI in Ayurveda include data privacy (given the sensitive nature of patient data), algorithmic bias, and the potential for discrimination against specific groups if training data sets are unbalanced or non-representative. To address this, developers must ensure transparency and accountability in AI systems and maintain human oversight to align AI functionality with human values and ethical principles.

Governance Frameworks

To navigate these risks, several nations, including India, are establishing comprehensive governance frameworks. The India AI Governance Guidelines address critical dimensions, including algorithmic transparency, risk classification, responsible use of generative AI, and safety and reliability testing. These frameworks require proactive measures, such as mandatory bias audits, independent ethics reviews, and clear delineation of responsibility between AI developers and healthcare providers, to build a trustworthy and robust AI ecosystem. Clear governance and regulatory pathways are non-negotiable prerequisites for the successful clinical deployment of AI-augmented traditional medicine.

REVIEW ARTICLE

AI in Regulatory Affairs

For Ayurvedic derivatives to achieve global regulatory acceptance, adherence to international pharmaceutical standards (e.g., FDA, EMA, ICH) is required. AI is proving to be a strategic enabler in this compliance process. AI-powered regulatory intelligence engines are now embedded across the regulatory lifecycle, utilizing generative AI to draft clinical study reports and labeling documents, and employing Natural Language Processing (NLP) to monitor evolving regulatory guidance in real-time. This capability allows regulatory teams to transition from reactive monitoring to proactive compliance, significantly improving the speed and scalability of document preparation and reducing time-to-IND (Investigational New Drug application). This AI-driven compliance infrastructure is essential for generating the evidence-based documentation required to advance traditional knowledge systems into global digital healthcare frameworks [25].

The table 2 summarizes the technical challenges and corresponding solutions necessary for successful AI integration in this specialized R&D domain.

Table 2 Challenges and Proposed Solutions for AI Integration in Ayurvedic R&D

Specific Issue	Impact on AI Model Development	Proposed Solution/Mitigation Strategy
Poor data fidelity, heterogeneity, complexity, and small datasets	Models lack robustness, suffer from inherent bias, limit prospective validation	Standardize structured data curation (e.g., IMPPAT refinement), use synthetic data augmentation (SMOTE)
Lack of standardization in traditional practices; contextual translation of Sanskrit literature	Difficult to develop generalizable tools; hinders integration of complex diagnostic data (e.g., Prakriti)	Foster collaboration between Vaidya-Scientists and tech experts; utilize AI-enabled platforms (Ayush Grid) for standardization
Data privacy, algorithmic bias, IP protection of Traditional Knowledge (TK)	Risk of discrimination, lack of transparency, and failure to align with human values	Implement mandatory bias audits; adhere to comprehensive governance frameworks (e.g., India AI); ensure human oversight



Figure 1 Steps of AI Vs Human Drug Discovery

CONCLUSIONS

Generative AI provides an unprecedented technological capacity to revolutionize *de novo* drug discovery by leveraging the rich, underexplored chemical space of Ayurvedic phytochemicals. Advanced architectures, particularly diffusion models integrated with equivariant graph neural networks, successfully generate novel, diverse, and geometrically plausible 3D molecular structures, addressing the pharmaceutical imperative for innovative scaffolds.

However, the reliable prediction of safety and efficacy for these novel compounds, especially

for complex herbal and herbomineral formulations, requires a transition beyond traditional computational models. The integrated Quantitative Knowledge- Activity Relationship **(QKAR)** framework is essential for reliable risk assessment. QKAR's superior ability to incorporate domain-specific knowledge offers the necessary mechanistic and risk differentiation needed for complex natural product derivatives, consistently outperforming structure-reliant QSAR models in predicting critical toxicities like **drug-induced liver injury**, and **drug-induced cardiotoxicity**.

The optimal pathway for translating this technological potential into globally accepted therapeutics involves integrating GAI/QKAR within the existing Reverse Pharmacology (RP) validation pipeline. RP provides the critical organizational structure for clinical validation, while GAI accelerates the early optimization and standardization of active markers, significantly shortening the development cycle for evidence-based phytomedicines . Achieving this translational goal hinges on immediate, coordinated investment in data standardization, resolving issues of data heterogeneity and ontology, and rigorously adhering to emerging ethical governance frameworks that mandate transparency and human oversight.

ACKNOWLEDGEMENT

We wish to acknowledge the foundational work provided by global researchers who have contributed to the digital mapping of natural product chemical space (e.g.IMPPAT) and those advancing the computational methods in equivariant geometric deep learning and knowledge-based toxicology that underpin this transformative field.

REFERENCES

1. Vamathevan, J., Clark, D., Czodrowski, P., et al. (2019). Applications of artificial intelligence in drug discovery and development. Nature Reviews Drug Discovery, 18 (6), 463–477.

2. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23 (6), 1241–1250.

3. Walters, W. P., & Barzilay, R. (2021). Applications of deep learning in molecule generation and optimization. Chemical Reviews, 121 (12), 6824–6870.

4. Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., et al. (2018). Automatic chemical design using a data-driven continuous representation of molecules. ACS Central Science, 4 (2), 268–276.

5. Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019). Deep learning for molecular design—A review of the state of the art. Molecular Systems Design & Engineering, 4 , 828–849.

6. Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 37 (9), 1038–1040.

7. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 1981 to 2019. Journal of Natural Products, 83 (3), 770–803.

8. Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015). The re-emergence of natural products for drug discovery in the genomics era. Nature Reviews Drug Discovery, 14 (2), 111–129.

9. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews Drug Discovery, 20 , 200–216.

10. Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014). Natural product and natural product derived drugs in clinical trials. Natural Product Reports, 31 , 1612–1661.

11. Patwardhan, B., & Mashelkar, R. A. (2009). Traditional medicine-inspired approaches to drug discovery: Can Ayurveda show the way forward? Drug Discovery Today, 14 (15–16), 804–811.

12. Patwardhan, B., Vaidya, A. D. B., & Chorghade, M. (2004). Ayurveda and natural products drug discovery. Current Science, 86 (6), 789–799.

13. Kadurin, A., Nikolenko, S., Khrabrov, K., Aliper, A., & Zhavoronkov, A. (2017). druGAN: An advanced generative adversarial autoencoder model for de novo generation of new molecules with desired molecular properties. Molecular Pharmaceutics, 14 (9), 3098–3104.

14. Blaschke, T., Olivecrona, M., Engkvist, O., Bajorath, J., & Chen, H. (2018). Application of generative autoencoder in de novo molecular design. Molecular Informatics, 37 (1–2), 1700123.

15. Hoogeboom, E., Satorras, V. G., Vignac, C., & Welling, M. (2022). Equivariant diffusion for molecule generation in 3D. In Proceedings of the 39th International Conference on Machine Learning (Vol. 162, pp. 8867–8880). PMLR.

16. Popova, M., Isayev, O., & Tropsha, A. (2018). Deep reinforcement learning for de novo drug design. Science Advances, 4 (7), eaap7885.

17. Meng, X. Y., Zhang, H. X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7 (2), 146–157.

18. Karplus, M., & McCammon, J. A. (2002). Molecular dynamics simulations of biomolecules. Nature Structural Biology, 9 (9), 646–652.

19. Tropsha, A. (2010). Best practices for QSAR model development, validation, and exploitation. Molecular Informatics, 29 (6–7), 476–488.

20. Brown, N., Fiscato, M., Segler, M. H. S., & Vaucher, A. C. (2019). GuacaMol: Benchmarking models for de novo molecular design. Journal of Chemical Information and Modeling, 59 (3), 1096–1108.

21. Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3 (11), 935–949.

22. Vedani, A., Dobler, M., & Smiesko, M. (2012). Virtual toxicology: Prediction of the toxic potential of chemicals using computational approaches. Journal of Medicinal Chemistry, 55 (17), 7177–7196.

23. Patwardhan, B. (2014). Reverse pharmacology: Synergy of Ayurveda and modern medicine. Journal of Ayurveda and Integrative Medicine, 5 (4), 243–245.

24. U.S. Food and Drug Administration. (2019). Proposed regulatory framework for modifications to artificial intelligence/machine learning-based software as a medical device . FDA.

25. Benjamens, S., Dhunnoo, P., & Meskó, B. (2020). The state of artificial intelligence-based FDA-approved medical devices and algorithms: An online database. NPJ Digital Medicine, 3, 118.